30

CLAIMS

1. Compounds of the formula (I)

$$(R_1)_i$$
 $(R_2)_j$
 (I)

in which:

5

10

15

20

- i and j = 1;
- R₁ is in position 3 or 4 on the phenyl ring and represents a cyano group, an alkoxy group substituted by halogen, a thioalkyl group, an alkylcarbonyl group or an alkylculfonyl group; and
- R₂ represents a carboxyl group, an alkoxycarbonyl group, an alkylcarbonyl group, an unsubstituted amide group or a linear or branched alkyl group substituted by a cyano, hydroxyl, carboxyl, alkoxycarbonyl or unsubstituted amide group; and also the pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions.
- 2. Compounds of the formula (I) according to Claim 1, in which R_2 is in position 3 or 4 on the phenyl ring.
- 3. Compounds of the formula (I) according to Claim 1 or 2, in which R₁ is chosen from the group consisting of -CN, -F, -CI, -SO₂CH₃, -COCH₃, -OCF₃ and -SCH₃ groups.
- 25 4. Compounds of the formula (I) according to one of Claims 1 to 3, in which R₂ is chosen from the group consisting of -CO₂C₂H₅, -COOH, -CH₂COOH, -CN, -COCH₃, -CONH₂ and -CH₂OH groups.

- 5. Compounds of the formula (I) according to one of Claims 1 to 4, chosen from the following compounds:
- 4-[(4-methoxyphenyl)amino]benzoic acid;
- {4-[(4-methoxyphenyl)amino]phenyl}methanol;
- 5 ethyl 4-[(4-cyanophenyl)amino]benzoate;
 - ethyl 4-[[4-(methylsulfonyl)phenyl]amino]benzoate;
 - 4-[(4-cyanophenyl)amino]benzoic acid;
 - 4-[[4-(methylsulfonyl)phenyl]amino]benzoic acid;
 - 3-[(4-methoxyphenyl)amino]benzoic acid;
- 10 {4-[(4-methoxyphenyl)amino]phenyl}acetic acid;
 - 1-{4-[(4-methoxyphenyl)amino]phenyl}ethanone;
 - 4-[(4-fluorophenyl)amino]benzoic acid;
 - 4-[(4-acetylphenyl)amino]benzoic acid;
 - 4-[(3-fluorophenyl)amino]benzoic acid;
- 15 {4-[(3-fluorophenyl)amino]phenyl}acetic acid;
 - {4-[(4-fluorophenyl)amino]phenyl}acetic acid;
 - 3-[(3-methoxyphenyl)amino]benzoic acid;
 - 4-[(3-chlorophenyl)amino]benzoic acid;
 - 3-[(4-acetylphenyl)amino]benzoic acid;
- 20 4-[[4-(methylsulfonyl)phenyl]amino]benzonitrile;
 - 3-[(4-acetylphenyl)amino]benzonitrile;
 - 4-{[4-(trifluoromethoxy)phenyl]amino}benzoic acid;
 - 4-[[4-(methylthio)phenyl]amino]benzoic acid;
 - {4-[(4-chlorophenyl)amino]phenyl}acetic acid;
- 25 {4-[(3-methoxyphenyl)amino]phenyl}acetic acid;
 - 4-[(3-cyanophenyl)amino]benzoic acid;
 - 4-[[3-(aminocarbonyl)phenyl]amino]benzoic acid;
 - {4-[[4-(methylsulfonyl)phenyl]amino]phenyl}acetic acid;
 - 4-[(3-chlorophenyl)amino]benzonitrile;
- 30 4-{[4-(trifluoromethoxy)phenyl]amino}benzonitrile;
 - 4-[(4-methoxyphenyl)amino]benzamide;
 - 4-[(4-nitrophenyl)amino]benzamide;

- 4-[(4-fluorophenyl)amino]benzamide;
- 4-{[4-(trifluoromethoxy)phenyl]amino}benzamide;
- 1-{4-[(4-chlorophenyl)amino]phenyl}ethanone;
- {4-[(4-fluorophenyl)amino]phenyl}methanol;
- 5 (4-{[4-(trifluoromethoxy)phenyl]amino}phenyl)methanol;
 - {4-[(3-chlorophenyl)amino]phenyl}methanol;
 - 3-[(4-fluorophenyl)amino]benzoic acid;
 - 4-{[4-(dimethylamino)phenyl]amino}benzoic acid;
 - (4-{[4-{dimethylamino)phenyl]amino}phenyl)methanol.

6. Pharmaceutical composition comprising a compound of the formula (II)

$$(R_1)_i$$
 $(R_2)_j$
 (II)

in which:

10

15

- R₁ represents, independently of each other, a halogen atom; an aliphatic hydrocarbon-based group optionally substituted and/or optionally interrupted by one or more oxygen or sulfur atoms; a nitro group; a cyano group; an amino group; a mono- or dialkylamino group; an alkylcarbonyl group; a carboxyl group; an alkylcarbonylamino group; an alkylsulfonyl group;
- R₂ represents, independently of each other, a cyano group; an hydroxyl group, an alkylcarbonyl group; a carboxyl group; an alkoxycarbonyl group; an unsubstituted amide group; or a linear or branched alkyl group substituted by a cyano, hydroxyl, carboxyl, alkoxycarbonyl or unsubstituted amide group.
- 25 i and j independently being from 1 to 5, and also the pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions in combination with a pharmaceutically acceptable excipient.

- 7. Composition according to Claim 6, in which R₂ is in position 3 or 4 on the phenyl ring.
- 8. Composition according to Claim 6 or 7, in which R₁ is chosen from the group consisting of -CN, -F, -Cl, -SO₂CH₃, -OCH₃, -COCH₃, -OCF₃, -SCH₃, -CF₃, -NO₂, -CH₃, -COOH, -CN, -CONH₂, -NHCOCH₃ and -N(CH₃)₂ groups.
- 9. Composition according to one of Claims 6 to 8, in which R₂ is chosen from the group consisting of -CO₂C₂H₅, -COOH, -CH₂COOH, -CN, -COCH₃,
 10 -CONH₂ and -CH₂OH groups.
 - 10. Composition according to one of Claims 6 to 9, in which the compound of the formula (II) is chosen from the following compounds:
 - 4-[(4-methoxyphenyl)amino]benzoic acid;
- 15 4-{[4-(trifluoromethyl)phenyl]amino}benzoic acid;
 - 4-[(4-methoxyphenyl)amino]benzonitrile;
 - {4-[(4-methoxyphenyl)amino]phenyl}methanol;
 - ethyl 4-[(4-nitrophenyl)amino]benzoate;
 - ethyl 4-[(4-cyanophenyl)amino]benzoate;
- 20 ethyl 4-{[4-(trifluoromethyl)phenyl]amino}benzoate;
 - ethyl 4-[[4-(methylsulfonyl)phenyl]amino]benzoate;
 - 4-[(4-nitrophenyl)amino]benzoic acid;
 - 4-[(4-cyanophenyl)amino]benzoic acid;
 - 4-[[4-(methylsulfonyl)phenyl]amino]benzoic acid;
- 25 3-[(4-methoxyphenyl)amino]benzoic acid;
 - {4-[(4-methoxyphenyl)amino]phenyl}acetic acid;
 - 1-{4-[(4-methoxyphenyl)amino]phenyl}ethanone;
 - 4-[(4-fluorophenyl)amino]benzoic acid;
 - 4-[(4-acetylphenyl)amino]benzoic acid;
- 30 4-[(3-fluorophenyl)amino]benzoic acid;
 - {4-[(3-fluorophenyl)amino]phenyl}acetic acid;
 - {4-[(4-fluorophenyl)amino]phenyl}acetic acid;

- 3-[(3-methoxyphenyl)amino]benzoic acid;
- 4-[(3-methylphenyl)amino]benzoic acid;
- 4-[(3-chlorophenyl)amino]benzoic acid;
- 3-[(4-acetylphenyl)amino]benzoic acid;
- 5 4-[[4-(methylsulfonyl)phenyl]amino]benzonitrile;
 - 3-[(4-acetylphenyl)amino]benzonitrile;
 - 4,4'-iminodibenzoic acid;
 - 4-{[4-(trifluoromethoxy)phenyl]amino}benzoic acid;
 - 4-[[4-(methylthio)phenyl]amino]benzoic acid;
- 10 {4-[(4-chlorophenyl)amino]phenyl}acetic acid;
 - {4-[(3-methoxyphenyl)amino]phenyl}acetic acid;
 - 4-[[4-(acetylamino)phenyl]amino]benzoic acid;
 - 4-[(3-cyanophenyl)amino]benzoic acid;
 - 4-[[3-(aminocarbonyl)phenyl]amino]benzoic acid;
- 15 (4-{[4-(trifluoromethyl)phenyl]amino}phenyl)acetic acid;
 - {4-[[4-(methylsulfonyl)phenyl]amino]phenyl}acetic acid;
 - 4-[(3-chlorophenyl)amino]benzonitrile;
 - 4-{[4-(trifluoromethoxy)phenyl]amino}benzonitrile;
 - 4-[(4-methoxyphenyl)amino]benzamide;
- 20 4-[(4-nitrophenyl)amino]benzamide;
 - 4-[(4-fluorophenyl)amino]benzamide;
 - 4-{[4-(trifluoromethoxy)phenyl]amino}benzamide;
 - 1-{4-[(4-chlorophenyl)amino]phenyl}ethanone;
 - {4-[(4-fluorophenyl)amino]phenyl}methanol;
- 25 (4-{[4-(trifluoromethoxy)phenyl]amino}phenyl)methanol;
 - N-{4-[[4-(hydroxymethyl)phenyl]amino]phenyl}acetamide;
 - {4-[(3-chlorophenyl)amino]phenyl}methanol;
 - {4-[(3-methylphenyl)amino]phenyl}methanol;
 - 3-[(4-fluorophenyl)amino]benzoic acid;
- 30 4-{[4-(dimethylamino)phenyl]amino}benzoic acid;
 - (4-{[4-{dimethylamino)phenyl]amino}phenyl)methanol.

- 11. Use of a compound of the formula (II) according to Claims 6 to 10, for the preparation of a medicament that is useful for the treatment of pathologies characterized by an oxidative stress condition.
- 5 12. Use of a compound of the formula (II) according to Claims 6 to 10, for the preparation of a medicament that is useful for the treatment of and preventing diabetes and/or metabolic insulin-resistance syndrome.
- 13. Use of a compound of the formula (II) according to Claims 6 to 10, for the preparation of a hypotriglyceridaemiant medicament.
 - 14. Use of a compound of the formula (II) according to Claims 6 to 10, for the preparation of an antioxidant medicament that can be used as a free-radical scavenger.